Gut microbiota: An intermediary between metabolic syndrome and cognitive deficits in schizophrenia.

Clicks: 424
ID: 121430
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #5 of 133 articles by views in progress in neuro-psychopharmacology & biological psychiatry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 133 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Gut microbiome interacts with the central nervous system tract through the gut-brain axis. Such communication involves neuronal, endocrine, and immunological mechanisms, which allows for the microbiota to affect and respond to various behaviors and psychiatric conditions. In addition, the use of atypical antipsychotic drugs (AAPDs) may interact with and even change the abundance of microbiome to potentially cause adverse effects or aggravate the disorders inherent in the disease. The regulate effects of gut microbiome has been described in several psychiatric disorders including anxiety and depression, but only a few reports have discussed the role of microbiota in AAPDs-induced Metabolic syndrome (MetS) and cognitive disorders. The following review systematically summarizes current knowledge about the gut microbiota in behavior and psychiatric illness, with the emphasis of an important role of the microbiome in the metabolism of schizophrenia and the potential for AAPDs to change the gut microbiota to promote adverse events. Prebiotics and probiotics are microbiota-management tools with documented efficacy for metabolic disturbances and cognitive deficits. Novel therapies for targeting microbiota for alleviating AAPDs-induced adverse effects are also under fast development.
Reference Key
zeng2020gutprogress Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zeng, CuiRong;Yang, Ping;Cao, Ting;Gu, YuXiu;Li, NaNa;Zhang, BiKui;Xu, Ping;Liu, YiPing;Luo, ZhiYing;Cai, HuaLin;
Journal progress in neuro-psychopharmacology & biological psychiatry
Year 2020
DOI
S0278-5846(20)30413-9
URL
Keywords
schizophrenia metabolic syndrome gut microbiota weight gain atypical antipsychotic drugs cognitive deficits

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.